RECRUITING

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedures that are burdensome and/or expensive. Smart devices (such as Apple or Fitbit) use light sensors (called "photoplethysmography" or PPG) and motion sensors (called "accelerometers") to continuously record biometric data, including heart rhythm. Smart devices are already widely adopted. This study seeks to validate an investigational machine-learning software (also called "algorithms") for the long-term monitoring and detection of abnormal cardiac rhythms using biometric data collected from consumer smart devices. The research team aims to enroll 500 subjects who are being followed after a stroke event of uncertain cause at the Emory Stroke Center. Subjects will undergo standard long-term cardiac monitoring (ECG), using FDA-approved wearable devices fitted with skin electrodes or implantable continuous recorders, and backed by FDA-approved software for abnormal rhythm detection. Patients will wear a study-provided consumer wrist device at home, for the 30 days of ECG monitoring, 23 hours a day. At the end of the 30 days, the device data will be uploaded to a secure cloud server and will be analyzed offline using proprietary software (called "algorithms") and artificial intelligence strategies. Detection of AF events using the investigational algorithms will be compared to the results from the standard monitoring to assess their reliability. Attention will be paid to recorded motion artifacts that can affect the quality and reliability of recorded signals. The ultimate aim is to establish that smart devices can potentially be used for monitoring purposes when used with specialized algorithms. Smart devices could offer an affordable alternative to standard-of-care cardiac monitoring.

Official Title

Develop and Validate Machine-Learning Algorithm to Detect Atrial Fibrillation With Wearable Devices

Quick Facts

Study Start:2023-03-21
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05795842

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults 55years of age or older.
  2. * Post-discharge with diagnostic of index ischemic stroke with uncertain cause.
  3. * Subject must be treated at the Emory Stroke Clinic for follow-up treatment.
  4. * Subject must be prescribed a clinical extended cardiac monitoring.
  5. * No diagnosis of AFib at the time of index stroke.
  6. * Subject or their Legal Authorized Representative (LAR) must be willing and able to provide informed consent.
  7. * Subject, family proxy, or caregiver must be able to understand English and the instructions necessary to manage and recharge the study wrist device.
  1. * Subject is younger than 55 years of age at the time of consent.
  2. * Subject has a diagnosis of AFib at the time of index stroke.
  3. * No indication for clinical extended cardiac monitoring.
  4. * Subject, family proxy, or caregiver unable to understand English and unable to follow the instructions on how to manage and recharge the study wrist device.
  5. * Subject has a diagnosis of structural valve disease, endocarditis, aortic arch atheroma \>3 mm, hypercoagulability, on lifelong anticoagulation, or has an active neoplastic disease
  6. * Subject or LAR is not willing or able to provide informed consent.

Contacts and Locations

Study Contact

Xiao Hu, PhD
CONTACT
404-712-8520
xhu40@emory.edu
Corey Williams
CONTACT
404-251-4060
corey.williams2@emory.edu

Principal Investigator

Xiao Hu, PhD
PRINCIPAL_INVESTIGATOR
Emory University, School of Nursing

Study Locations (Sites)

Emory Clinic
Atlanta, Georgia, 30322
United States

Collaborators and Investigators

Sponsor: Emory University

  • Xiao Hu, PhD, PRINCIPAL_INVESTIGATOR, Emory University, School of Nursing

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-21
Study Completion Date2028-12

Study Record Updates

Study Start Date2023-03-21
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • Cardiac monitoring
  • Atrial Fibrillation

Additional Relevant MeSH Terms

  • Stroke, Ischemic